HYQVIA Drug Profile

Summary for Tradename: HYQVIA

High Confidence Patents:	1
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for HYQVIA

Recent Clinical Trials for HYQVIA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Baxalta now part of Shire	Phase 1
Baxalta Innovations GmbH, now part of Shire	Phase 1
University Hospital, Lille	Phase 4

See all HYQVIA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HYQVIA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for HYQVIA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	HYQVIA	immune globulin infusion (human), 10% with recombinant human hyaluronidase	Injection	125402		2024-03-05	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for HYQVIA Derived from Patent Text Search

No patents found based on company disclosures

International Patents for HYQVIA

Country	Patent Number	Estimated Expiration
Austria	E448323
Australia	2004218354
Australia	2006216545
Australia	2009245838
Australia	2013202475
Brazil	PI0408116
Brazil	PI0608314

Supplementary Protection Certificates for HYQVIA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C02163643/01	Switzerland		PRODUCT NAME: TRASTUZUMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65964 24.11.2016
C20160022 00413	Estonia		PRODUCT NAME: RITUKSIMAB JS REKOMBINANTNE INIMESE HUEALURONIDAAS;REG NO/DATE: EU/1/98/067 26.03.2014
132016000070123	Italy		PRODUCT NAME: RITUXIMAB IN ASSOCIAZIONE CON IALURONIDASI RICOMBINANTE UMANA - SOLUZIONE PER INIEZIONE SOTTOCUTANEA(MABTHERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/98/067/001-003, 20140326
C02405015/01	Switzerland		PRODUCT NAME: RITUXIMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65813 28.06.2016
PA2016022	Lithuania		PRODUCT NAME: RITUKSIMABAS; REGISTRATION NO/DATE: EU/1/98/067/001-002 20140321
C201530049	Spain		PRODUCT NAME: TRASTUZUMAB Y HIALURONIDASA HUMANA RECOMBINANTE; NATIONAL AUTHORISATION NUMBER: EU/1/100/145/002; DATE OF AUTHORISATION: 20130826; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/100/145/002; DATE OF FIRST AUTHORISATION IN EEA: 20130826
PA2015031	Lithuania		PRODUCT NAME: TRASTUZUMABAS IR REKOMBINANTINE ZMOGAUS HIALURONIDAZE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826

Market Dynamics and Financial Trajectory for HYQVIA

Last updated: April 18, 2026

What is the Current Market Position of HYQVIA?

HYQVIA (immune globulin субcutaneous infusion with recombinant human hyaluronidase) is a biologic approved for primary immunodeficiency (PI) and secondary immunodeficiency. It combines immunoglobulin G (IgG) with recombinant human hyaluronidase (rHuPH20) that enhances subcutaneous absorption. Approved by the FDA in 2017, it targets the US and European markets.

As of 2023, HYQVIA is the only subcutaneous immunoglobulin (SCIG) combining IgG with hyaluronidase, offering an alternative to traditional intravenous (IVIG) therapies. It competes with other SCIG products, such as Hizentra (CSL Behring) and Vivaglobin (Grifols).

Estimates of market penetration suggest moderate adoption, driven primarily by patients needing high doses and those preferring home-based subcutaneous therapy over infusions administered in clinics.

How Does the Market Demand Evolve for HYQVIA?

Factors influencing demand include:

• Patient Preference: Increasing preference for subcutaneous over intravenous administration due to convenience and fewer systemic side effects.
• Regulatory Approvals: Rapid approvals in key regions bolster market access. Besides the US and EU, availability expands via local regulatory processes.
• Patient Population Growth: The primary immunodeficiency (PI) population in the US is estimated at 40,000–50,000 patients (Ramakrishnan et al., 2021).
• Pricing and Reimbursement: Payers often favor less costly SCIG therapies; however, HYQVIA’s premium pricing and reimbursement policies affect uptake.

Market research projects compound annual growth rates (CAGR) of approximately 8–10% in the global immunoglobulin segment through 2028, with subcutaneous formulations like HYQVIA sharing part of this growth.

What Are the Key Drivers and Barriers in HYQVIA's Financial Outlook?

Drivers:

• Efficacy and Safety Profile: Proven effective with a favorable safety profile; supports patient adherence.
• Flexible Dosing: Supports both weekly and bi-weekly administration.
• Reduced Hospital Visits: Cost savings through home therapy compared to clinic-based IVIG.
• Market Expansion: Growing awareness and expanding indications.

Barriers:

• Competition: Other SCIG products with established market share.
• Pricing Constraints: Reimbursement challenges and high costs limit adoption.
• Limited Indication Expansion: Currently restricted to immunodeficiency; potential for wider use remains uncertain.
• Patient Preference: Some patients prefer IVIG or other SCIG formulations due to familiarity.

What Is the Financial Trajectory of HYQVIA?

Revenue Estimates

HYQVIA’s sales are reported in Global Immunoglobulin revenues, which reached approximately $20 billion in 2022 (EvaluatePharma, 2022). While direct sales figures are proprietary, industry sources estimate HYQVIA’s contribution at estimated $250–$400 million annually, representing a small but growing share.

Growth Projections

Analysts forecast a CAGR of 8–10% for the overall immunoglobulin segment. HYQVIA's share is expected to grow at similar rates driven by:

• Increased demand in the US, where primary immunodeficiency prevalence is rising.
• Expansion into additional markets such as Japan and emerging regions.
• Ongoing clinical trials exploring new indications (e.g., autoimmune diseases).

Cost and Profitability

Manufacturing costs are high, typical of biologics, with gross margins in the 60–70% range. As the company scales, economies of scale could improve profit margins. Reimbursement policies heavily influence net revenue.

Patent and Licensing

HYQVIA’s patent portfolio extends until approximately 2030. No significant patent challenges currently threaten exclusivity, but competitors may develop biosimilars after patent expiry.

What Are Competitive and Regulatory Trends Impacting HYQVIA?

• Biosimilar Entry: Biosimilar immunoglobulins are unlikely in the short term due to complex manufacturing and regulatory barriers.
• Regulatory Landscape: The FDA and EMA provide pathways for expanding indications, which could enhance revenue streams.
• Pricing Policies: Global pressures for cost containment could result in price reductions or reimbursement caps.

Conclusion

HYQVIA operates in a growing segment of the biologic immunoglobulin market. Its financial trajectory depends on market acceptance, competitive dynamics, regulatory support, and reimbursement policies. Current data suggest moderate but steady revenue growth with expansion opportunities in emerging markets and additional indications.

Key Takeaways

• HYQVIA's market share remains limited but is supported by increasing demand for subcutaneous immunoglobulins.
• Revenue estimates range from $250–$400 million annually, with 8–10% CAGR forecast over the next five years.
• Growth is hindered by competition, reimbursement challenges, and patient preference for other therapies.
• Patent protections extend until 2030, delaying biosimilar competition.
• Expanding indications and geographic reach could significantly alter its market dynamics.

FAQs

1. How does HYQVIA compare to other immunoglobulin therapies?
HYQVIA combines IgG with hyaluronidase, allowing larger doses subcutaneously at home. It offers convenience over IVIG but competes with other SCIG products like Hizentra, which lacks hyaluronidase.

2. What patient population primarily uses HYQVIA?
Patients with primary immunodeficiency and secondary immunodeficiency requiring regular immunoglobulin replacement therapy.

3. What are the main barriers to growth for HYQVIA?
Competition from established SCIG products, reimbursement constraints, patient preference, and high manufacturing costs.

4. Are there any approvals for indications beyond immunodeficiency?
Current approvals include primary and secondary immunodeficiency. Clinical trials are exploring autoimmune and inflammatory indications, but no approvals are granted yet.

5. When is biosimilar competition likely to emerge?
Biosimilar immunoglobulins are unlikely before 2030 due to complex manufacturing and regulatory challenges, aligning with patent expiry timelines.

---

References

[1] EvaluatePharma. (2022). Global Immunoglobulin Market Data.
[2] Ramakrishnan, S., et al. (2021). Epidemiology of primary immunodeficiencies. Journal of Immunology, 206(3), 816-825.